Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-15

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

FDA approved a supplemental application for a Sun Pharmaceutical generic combination of buprenorphine and naloxone for treating opioid dependence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)